Thermo Fisher Scientific IncNYSE: TMO
Health Care · Life Sciences Tools & Services
$466.53
+1.05%
Vol: 1.5M
Research Digest
Friday, June 19, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 18Piper Sandler initiates Thermo Fisher at Neutral with $510 target while Barclays issues a Buy; stock trades ~23% below consensus fair value.Neutral▶
On June 11, 2026, Piper Sandler initiated coverage of Thermo Fisher Scientific (NYSE: TMO) with a Neutral rating and a $510 price target, flagging near-term caution on the life-sciences tools recovery timeline. On June 8, Barclays issued a Buy rating on TMO, with the Street mean target around $603 across 27 analysts (18 Buy, 5 Outperform, 4 Hold). TMO shares were trading at approximately $461–$472 on June 17, down roughly 20% YTD, implying a ~23% discount to consensus fair value. The company declared a $0.47 quarterly dividend payable July 15 and showcased new Orbitrap Apex and Excedion mass spectrometers at ASMS 2026 in San Diego (June 1–4). Risk: diverging analyst views and YTD underperformance reflect uncertainty over the pace of pharma/biotech customer spending recovery.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Thermo Fisher hosts 2026 Investor Day May 20, targeting 7% organic revenue growth and low-teens adjusted EPS growth long-term.Positive▶
Thermo Fisher Scientific held its 2026 Investor Day on May 20 in New York, where senior management presented long-term targets of 7% organic revenue growth and low-teens adjusted EPS growth, with continued expansion in drug development and bioprocessing. The company recently signed a definitive agreement to sell its microbiology business to European PE firm Astorg for ~$1.075 billion (cash plus a $50M seller note), expected to close in 2H 2026. Q1 FY26 revenue reached $11.01B (+6% YoY) and adjusted EPS of $5.44 beat expectations of $5.25. The board declared a $0.47 quarterly dividend. Consensus analyst rating is Strong Buy with an average target of $611.56.
May 20Thermo Fisher to host 2026 Investor Day May 20 after agreeing to sell microbiology business to Astorg for ~$1.075B.Positive▶
Thermo Fisher Scientific holds its 2026 Investor Day on Wednesday, May 20, at 9:00 a.m. ET, a key catalyst for the stock. The company recently signed a definitive agreement to divest its microbiology business (which generated $645M in 2025 revenue) to European PE firm Astorg for approximately $1.075B, consisting of cash plus a $50M seller note. Q1 2026 results showed revenue growth of 6% to $11.01B and GAAP EPS up 11% to $4.43, with $3.0B of buybacks and a 10% dividend hike. Morgan Stanley's Kallum Titchmarsh trimmed his price target to $620 from $670 but kept an Overweight rating. Consensus is Strong Buy with an average target near $611.56. Risks include life-sciences instrument demand softness and exposure to biopharma capex cycles.
May 19Thermo Fisher hosts 2026 Investor Day May 20 as Morgan Stanley trims price target despite Q1 beatMixed▶
Thermo Fisher holds its 2026 Investor Day on May 20 in New York. Q1 FY26 revenue reached $11.01B (+6% YoY, vs. $10.87B est.) and adjusted EPS of $5.44 topped the $5.25 consensus, though shares fell ~9% with six analysts revising estimates lower on acquisition-related charges. Morgan Stanley analyst Kallum Titchmarsh cut the price target to $620 from $670 while maintaining Overweight. Thermo signed a $1.075B agreement to sell its microbiology business to Astorg, expected to close in H2 2026. The company also launched the Gibco CTS DynaXS single-use bioreactor on May 4 for cell therapy scale-up. Risk: continued post-earnings derating despite operational beats.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 15Thermo Fisher to sell microbiology business to Astorg for ~$1.075B; 2026 Investor Day set for May 20Positive▶
Thermo Fisher signed a definitive agreement (announced April 27, 2026) to sell its microbiology business to private-equity firm Astorg for approximately $1.075 billion, consisting of cash and a $50 million seller note, completing portfolio optimization. The company will host its 2026 Investor Day on Wednesday, May 20 at 9:00 a.m. ET — a key catalyst for forward guidance. Q1 2026 results showed revenue up 6% to $11.01 billion and GAAP diluted EPS up 11% to $4.43, with full-year 2026 guidance raised. The company completed its Clario acquisition, repurchased $3.0 billion of stock, raised the dividend 10%, and announced strategic collaborations with NVIDIA (AI-powered scientific instrumentation) and SHL Medical (sterile fill-finish manufacturing). Analyst consensus is Strong Buy with average $632 PT (~38% upside).
May 14Thermo Fisher to host Investor Day May 20 in NYC; struck deal to divest microbiology business to Astorg for ~$1.075B; stock down 22% YTD despite Q1 beat and raised guidance.Mixed▶
Thermo Fisher Scientific will host its 2026 Investor Day on Wednesday, May 20, 2026 at 9:00 a.m. ET in New York City, featuring senior management presentations and Q&A. The company recently struck a deal to sell its microbiology business to European private-equity firm Astorg for approximately $1.075 billion. In April and early May 2026, TMO launched the Gibco CTS DynaXS Single Use Bioreactor for scalable bioproduction. Despite Q1 2026 revenue up 6% to $11.01B, GAAP EPS up 11% to $4.43, and updated 2026 guidance of $47.3B-$48.1B revenue / $24.64-$25.12 adjusted EPS, shares closed near $462.60 — about 22% below year-start levels. Consensus is Strong Buy with a 12-month PT of $632.47 (~37.6% upside). Risk: investor day on May 20 carries event risk; ongoing share-price weakness reflects bioprocessing/academic funding concerns despite improving fundamentals.
May 13Thermo Fisher Scientific to host 2026 Investor Day on May 20 after announcing a $1.075B microbiology business divestiture to Astorg.Positive▶
Thermo Fisher Scientific will hold its 2026 Investor Day on May 20, 2026 in New York City. The company struck a deal to sell its microbiology business to European private-equity firm Astorg for approximately $1.075 billion, while expanding offerings in cell therapy and hydration. Jim Cramer endorsed buying at current levels, noting IPO demand for TMO machines. Stock trades at $459.29 with an average analyst rating of Strong Buy and 12-month target of $632.47 (37.59% upside).
May 12Thermo Fisher Scientific to host 2026 Investor Day in NYC on May 20 amid stock's ~22% YTD slump despite Q1 beat and guidance raise.Neutral▶
Thermo Fisher will host its 2026 Investor Day on Wednesday, May 20 at 9:00 a.m. ET in New York City, featuring senior management presentations and a Q&A session. The event comes with shares around $462.60, roughly 22% below year-start levels despite Q1 2026 revenue growth of 6% to $11.01B and adjusted EPS of $5.44. Updated 2026 guidance calls for revenue of $47.3B-$48.1B and adjusted EPS of $24.64-$25.12. Recent moves include the launch of the Gibco CTS DynaXS Single Use Bioreactor and the announced sale of its microbiology business to Astorg for over $1B. Average 12-month analyst price target is ~$632, implying significant upside.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| TMOTHERMO | $466.53 | +1.05% | +2.8% | 17.1x | 0.87 | $172.7B |
| DHRDANAHER | $177.74 | -0.01% | +3.5% | 19.1x | 0.83 | $125.4B |
| AAGILENT | $127.36 | +2.44% | +11.7% | 19.2x | 1.26 | $35.9B |
| WATWATERS | $356.50 | -0.14% | +4.1% | 21.6x | 1.20 | $34.9B |
| IQVIQVIA | $168.20 | -1.45% | -2.2% | 11.8x | 1.22 | $28.0B |
| MTDMETTLER | $1,150.03 | +1.81% | +5.7% | 22.3x | 1.26 | $23.1B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.